Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040086 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,454
- Enrollment target
- 20
- Study locations
NCT06040086: Active Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
NCT06040086 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,454 participants, above the 611-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (138% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06040086, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,454 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment.
Primary Outcome
The primary endpoint will be assessed in the primary population (former smokers with symptomatic COPD and a history of exacerbations, on optimised treatment with maintenance inhaled therapy \[triple therapy, or dual therapy if triple is not considered appropriate\]).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tozorakimab
Study Locations (20)
Florida
- Research Site - Boynton Beach
- Research Site - Cape Coral
- Research Site - Lakeland
- Research Site - Lakeland
- Research Site - Naples
- Research Site - Ocala
- Research Site - Ormond Beach
California
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - San Francisco
- Research Site - Westminster
Alabama
- Research Site - Birmingham
- Research Site - Decatur
- Research Site - Sheffield
Arizona
- Research Site - Phoenix
- Research Site - Tucson
- Research Site - Yuma
Colorado
- Research Site - Aurora
- Research Site - Boulder
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,454 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2026-05-22 |
| Phase | Phase 3 |
What the registry record for NCT06040086 still lists
NCT06040086 is an interventional study that assigns participants to a tested intervention. Its 1,454 participants enrollment target places it among the larger protocols in the corpus, above the 611-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (138% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06040086 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06040086 about?
NCT06040086 is a clinical study titled "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations". The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiv...
What is the current status of trial NCT06040086?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,454 participants. The study started on 2023-09-22. Estimated completion is 2026-05-22.
What conditions does trial NCT06040086 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT06040086?
The interventions under investigation include: Placebo (DRUG), Tozorakimab (DRUG).
Who is sponsoring clinical trial NCT06040086?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06040086 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06040086's enrollment target sits among peer trials
1,454 4th of 36 higher than 33 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI